JPWO2019136307A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019136307A5 JPWO2019136307A5 JP2020557124A JP2020557124A JPWO2019136307A5 JP WO2019136307 A5 JPWO2019136307 A5 JP WO2019136307A5 JP 2020557124 A JP2020557124 A JP 2020557124A JP 2020557124 A JP2020557124 A JP 2020557124A JP WO2019136307 A5 JPWO2019136307 A5 JP WO2019136307A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- use according
- seq
- interaction
- modulates
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 27
- 101150013553 CD40 gene Proteins 0.000 claims description 17
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 17
- 102100032937 CD40 ligand Human genes 0.000 claims description 14
- 230000003993 interaction Effects 0.000 claims description 9
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 108010029697 CD40 Ligand Proteins 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 210000001185 bone marrow Anatomy 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 claims 1
- 108010027279 Facilitative Glucose Transport Proteins Proteins 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 102000013691 Interleukin-17 Human genes 0.000 claims 1
- 108050003558 Interleukin-17 Proteins 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 230000003393 splenic effect Effects 0.000 claims 1
- 238000004458 analytical method Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 102000013918 Apolipoproteins E Human genes 0.000 description 2
- 108010025628 Apolipoproteins E Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 210000002376 aorta thoracic Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000012754 cardiac puncture Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024097199A JP2024123100A (ja) | 2018-01-05 | 2024-06-17 | 自己免疫関連疾患を治療するための治療用ペプチドおよび方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862614262P | 2018-01-05 | 2018-01-05 | |
| US62/614,262 | 2018-01-05 | ||
| US16/184,129 | 2018-11-08 | ||
| US16/184,129 US20190194290A1 (en) | 2010-10-19 | 2018-11-08 | Methods for preventing, modulating and/or reducing cardiovascular disease |
| PCT/US2019/012425 WO2019136307A1 (en) | 2018-01-05 | 2019-01-04 | Therapeutic peptides and methods for treating autoimmune related disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024097199A Division JP2024123100A (ja) | 2018-01-05 | 2024-06-17 | 自己免疫関連疾患を治療するための治療用ペプチドおよび方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021510174A JP2021510174A (ja) | 2021-04-15 |
| JPWO2019136307A5 true JPWO2019136307A5 (zh) | 2023-06-19 |
| JP7511242B2 JP7511242B2 (ja) | 2024-07-05 |
Family
ID=67144298
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020557124A Active JP7511242B2 (ja) | 2018-01-05 | 2019-01-04 | 自己免疫関連疾患を治療するための治療用ペプチドおよび方法 |
| JP2024097199A Pending JP2024123100A (ja) | 2018-01-05 | 2024-06-17 | 自己免疫関連疾患を治療するための治療用ペプチドおよび方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024097199A Pending JP2024123100A (ja) | 2018-01-05 | 2024-06-17 | 自己免疫関連疾患を治療するための治療用ペプチドおよび方法 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP3735260A4 (zh) |
| JP (2) | JP7511242B2 (zh) |
| CN (1) | CN111801110A (zh) |
| AU (1) | AU2019205328A1 (zh) |
| BR (1) | BR112020013716A2 (zh) |
| CA (1) | CA3086193A1 (zh) |
| MX (1) | MX2020007081A (zh) |
| SG (1) | SG11202006494VA (zh) |
| WO (1) | WO2019136307A1 (zh) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2957957T3 (es) | 2010-10-19 | 2024-01-30 | Op T Llc | Péptidos para modular la actividad de linfocitos T y usos de los mismos |
| US11793854B2 (en) | 2019-03-21 | 2023-10-24 | Op-T Llc | Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD150 interaction |
| JP2022540731A (ja) | 2019-07-12 | 2022-09-16 | オーピー－ティー エルエルシー | ペプチドおよび疾患の治療方法 |
| EP4135742A2 (en) * | 2020-04-17 | 2023-02-22 | Op-T Llc | Bioactive peptides and methods of use thereof |
| US20220031632A1 (en) * | 2020-05-14 | 2022-02-03 | Op-T Llc | Nanoparticle compositions and uses thereof |
| WO2022036495A1 (en) | 2020-08-17 | 2022-02-24 | Utc Therapeutics Inc. | Lymphocytes-antigen presenting cells co-stimulators and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7495090B2 (en) * | 2002-05-23 | 2009-02-24 | The Regents Of The University Of California | Nucleic acids encoding chimeric CD154 polypeptides |
| US20070041971A1 (en) * | 2003-07-07 | 2007-02-22 | Wagner David H | Methods for predicting development of auto-immune diseases and treatment of same |
| US7449200B2 (en) * | 2006-04-17 | 2008-11-11 | Gp Medical, Inc. | Nanoparticles for protein/peptide delivery and delivery means |
| ES2957957T3 (es) * | 2010-10-19 | 2024-01-30 | Op T Llc | Péptidos para modular la actividad de linfocitos T y usos de los mismos |
| FI3421486T3 (fi) * | 2012-06-22 | 2023-12-15 | Dartmouth College | Uusia vista-ig-rakenteita ja vista-ig:n käyttö autoimmuuni-, allergia- ja tulehdushäiriöiden hoitamiseksi |
| EP3123176A4 (en) * | 2014-03-23 | 2018-04-25 | The Regents of the University of Colorado | Diagnosis of multiple sclerosis in human and animal subjects |
-
2019
- 2019-01-04 WO PCT/US2019/012425 patent/WO2019136307A1/en unknown
- 2019-01-04 CN CN201980017176.9A patent/CN111801110A/zh active Pending
- 2019-01-04 EP EP19736089.4A patent/EP3735260A4/en active Pending
- 2019-01-04 BR BR112020013716-2A patent/BR112020013716A2/pt unknown
- 2019-01-04 SG SG11202006494VA patent/SG11202006494VA/en unknown
- 2019-01-04 CA CA3086193A patent/CA3086193A1/en active Pending
- 2019-01-04 MX MX2020007081A patent/MX2020007081A/es unknown
- 2019-01-04 AU AU2019205328A patent/AU2019205328A1/en active Pending
- 2019-01-04 JP JP2020557124A patent/JP7511242B2/ja active Active
-
2024
- 2024-06-17 JP JP2024097199A patent/JP2024123100A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW400233B (en) | Pharmaceutical compositions comprising IL-12 antagonists for treating autoimmune diseases | |
| JP3866197B2 (ja) | 虚血性疾患治療剤 | |
| US5840770A (en) | Method of killing tumor cells | |
| JP2805224B2 (ja) | 血小板減少症治療剤 | |
| KR102357275B1 (ko) | 심부전을 치료하기 위한 뉴레귤린의 연장 방출 | |
| Hinshaw et al. | Effectiveness of steroid/antibiotic treatment in primates administered LD100 Escherichia coli. | |
| EP0722324A1 (en) | Pharmaceutical composition for immunoenhancement therapy | |
| JP2020502150A5 (zh) | ||
| JP2020502151A5 (zh) | ||
| WO2021244010A1 (zh) | 热休克因子2结合蛋白在肝脏缺血再灌注损伤、药物性肝损伤中的应用 | |
| JP2023012515A5 (zh) | ||
| CN102552883A (zh) | 一种多肽复合物、药物组合物、其制备方法和应用 | |
| JPWO2019136307A5 (zh) | ||
| JP2021530553A (ja) | 標的サイトカイン枯渇による腎臓病の再発の抑制 | |
| US9555070B2 (en) | Pan-antiviral peptides for protein kinase inhibition | |
| Ono et al. | First-in-man clinical pilot study showing the safety and efficacy of intramuscular injection of basic fibroblast growth factor with atelocollagen solution for critical limb ischemia | |
| PT2077852E (pt) | Agente compreendendo g-csf para prevenção e tratamento de neuropatia diabética periférica | |
| Stinco et al. | Hypertriglyceridaemia during treatment with adalimumab in psoriatic arthritis | |
| Henderson et al. | Hyperglycemia in acutely ill emergency patients—Cause or effect? | |
| CN103656639B (zh) | 不规则趋化因子的中和抗体用于制备消除糖尿病心肾功能损害不良代谢记忆的药物的用途 | |
| Arya et al. | Cell-Based Gene Therapy for β-Thalassemia | |
| CN112023031A (zh) | SNase在制备促进糖尿病伤口愈合药物中的应用 | |
| Billings et al. | Efficacy of IDegLira vs. Basal–Bolus Therapy in Subjects with Type 2 Diabetes in DUAL VII by Baseline Characteristics | |
| Gabrilove | New strategies and treatment modalities for optimizing patient outcomes | |
| Gao et al. | The protective effect of a short peptide derived from cold-inducible RNA-binding protein in a rat model of cardiac arrest and resuscitation |